AIM ImmunoTech Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| AIM | IMNN | IMRN | IMM.L | DTC.CN | INMB | |
|---|---|---|---|---|---|---|
| Market cap | 6.42M | 5.09M | 6.88M | 20.16M | 25.50M | 41.18M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -0.4 | -0.5 | -85.3 | 0.0 | — | -3.1 |
| Price/book | 0.6 | 2.2 | 0.9 | 10.7 | 7.3 | 1.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −90.78% | −77.50% | −43.05% | −67.26% | −63.04% | −25.42% |
| Today | +0.19% | +0.78% | −0.84% | −0.96% | −1.47% | +0.76% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All AIM news ›AIM ImmunoTech Announces Release of the Next CEO Corner Segment
OCALA, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the next CEO Corner segment has been published on the Company’s website ... AIM ImmunoTech Announces Release…
AIM ImmunoTech’s Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays
Primary and secondary endpoint reporting remains pending after completion of Ampligen dosing in the DURIPANC combination trial. CEO video reported the same exploratory subgroup median survival of 34.8 months from FOLFIRINOX start. DURIPANC…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- globenewswire.com2
- natlawreview.com1
- quiverquant.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 4 articles, not a forecast.